Authors
Latest:
FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaThe FDA has approved pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma following at least 2 lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.
Latest:
Gathering Medical Information: MerckMedicus and MerckSourceMs. Gerhart is manager of pharmacy affairs at Merck & Co Inc.
Latest:
Rise of Oncology Value-Based Care Creates New Imperative for Data TrackingThe rise in value-based reimbursement models has required oncology care providers to assume an unprecedented level of accountability.
Latest:
HRSA Wants to Audit Your 340B Program. Are You Ready? 5 Best Practices for Operating a Compliant 340B ProgramIt's Friday afternoon and your hospital receives an e-mail from the Health Resources and Services Administration, notifying you that your hospital has been selected for a 340B program audit. Are you ready?
Latest:
"American Patients First" Plan Marks a Good First Step: Here's What Should Happen Next to Lower Drug CostsWith American Patients First, the administration is doing its part to improve prescription drug affordability—now it’s time for Congress to do theirs.
Latest:
Impact of Medicaid Preferred Drug List on Long-Acting Opioid UsersAn opioid preferred drug list was not associated with an increase in emergency department visits or hospitalizations in a Medicaid population.
Latest:
The Pharma PharmacistDoes the prospect of continuing lower reimbursement rates, crazy hours, longer phone wait times, and slow and inefficient pharmacy software have you considering a new career?
Latest:
Delivering Evidence-Based Value to Cancer PatientsSpecialty Pharmacy Times spoke with Dr. Neubauer to discuss the intricacies of clinical pathways, including how to reconcile a drug's cost and benefits, the importance of making evidence-based decisions, when to deviate from recommended treatment pathways, and why he thinks all health plans should pay for the routine costs of clinical trials.
Latest:
What Keeps You Up at Night?Our new department focuses on the issues that the industry faces as it is held to very high standards of compliance with minimal guidance. So what are the rules to be in compliance?
Latest:
Impact of Insulin Delivery Systems in Elderly Patients With Type 2 DiabetesThis real-world study suggests that improved clinical outcomes are possible in the difficult-to-treat elderly patients with type 2 diabetes group without affecting healthcare costs, by initiating insulin therapy with a pen device.
Latest:
The Evolution of Pneumococcal Vaccines and Current GuidelinesPharmacists are in an excellent position to educate and counsel patients on current recommendations.
Latest:
Using the Patient Care Process in the Community: Patient-Oriented CareCommunity pharmacists are valuable health care providers given their accessibility and distribution throughout the community, extended hours of operation, and clinical knowledge.
Latest:
Prevention of Shingles: The Zostavax VaccineDr. Patel is a clinical assistant professor in the Department of Pharmacy Practice, Oregon State University/ Oregon Health & Science University, College of Pharmacy, Portland campus.
Latest:
The Importance of Outcomes in High Cost Drug TherapiesPharmaceutical manufacturers historicially reaped the benefits of operating independently in pricing and discounting drugs based on volume sold in the United States.
Latest:
Exploring the History and Rise of Data Opportunity SystemsThe opportunity to leverage patient immunization history and data at the point of care in a pharmacy environment can increase the trust and credibility of the pharmacist as a member of the patient’s health care team.
Latest:
Quality Initiatives: Pharmacists in the ForefrontPharmacists can lead quality transformation within their organizations.
Latest:
Renin Antagonists: An Alternative to Controlling HypertensionIdentification of aliskiren's role in the management of hypertension has been the focus of several clinical trials which have demonstrated its effectiveness in blood pressure reduction with few side effects.
Latest:
Not Just Dispensing: The Unique Role of Pharmacists in an Outpatient Research PharmacyPharmacists can serve as essential members of a research team in a role that involves much more than traditional dispensing functions.
Latest:
The Role of PARP Inhibitors in Treating Ovarian CancerRucaparib is FDA approved in patients with a BRCA mutation and who have received 2 more prior lines of previous chemotherapy.
Latest:
The Opportunities and Challenges of Specialty DistributionThe distribution of infusible specialty medications comes with difficulties that must be addressed by pharmacies and payers.
